A detailed history of Caxton Associates LLP transactions in Incyte Corp stock. As of the latest transaction made, Caxton Associates LLP holds 6,681 shares of INCY stock, worth $695,826. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,681
Previous 11,434 41.57%
Holding current value
$695,826
Previous $779 Million 99.93%
% of portfolio
0.01%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 17, 2025

SELL
$67.27 - $86.96 $319,734 - $413,320
-4,753 Reduced 41.57%
6,681 $566,000
Q2 2025

Aug 14, 2025

SELL
$55.17 - $71.22 $893,864 - $1.15 Million
-16,202 Reduced 58.63%
11,434 $779 Million
Q1 2025

May 15, 2025

BUY
$60.0 - $75.26 $1.66 Million - $2.08 Million
27,636 New
27,636 $1.67 Billion

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $23.2B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Caxton Associates LLP Portfolio

Follow Caxton Associates LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LLP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LLP with notifications on news.